Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03428984 · ClinicalTrials.gov registry record · Phase 1
Study in Adult Subjects Undergoing Posterolateral Thoracotomy
A Phase 1 study, sponsored by Pacira Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03428984 is a Phase 1 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT03428984, a Phase 1 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Primary Objective: To characterize the pharmacokinetic (PK) profile of EXPAREL when administered as a posterior intercostal nerve block. Secondary Objective: To assess the safety and tolerability of EXPAREL in this surgical model.
Interventions
- DRUG EXPAREL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03428984
The ClinicalTrials.gov registry entry for NCT03428984 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXPAREL is the first listed.
NCT03428984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03428984 about?
NCT03428984 is a clinical study titled "Study in Adult Subjects Undergoing Posterolateral Thoracotomy". Primary Objective: To characterize the pharmacokinetic (PK) profile of EXPAREL when administered as a posterior intercostal nerve block. Secondary Objective: To assess the safety and tolerability of EXPAREL in this surgical model.
What is the current status of trial NCT03428984?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-05-03. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT03428984?
The interventions under investigation include: EXPAREL (DRUG).
Who is sponsoring clinical trial NCT03428984?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.